ABI2: A Promising Drug Target / Biomarker (G10152)
ABI2: A Promising Drug Target / Biomarker
Advanced Bioelectronics (ABI2) is a technology that has the potential to revolutionize the way we diagnose and treat disease. Developed by researchers at the University of California, San Diego, ABI2 is a novel platform that uses nanotubes to enhance the sensitivity and accuracy of diagnostic tests. The technology has the potential to replace existing diagnostic methods, making it a promising drug target and biomarker for researchers to explore.
The ABI2 Technology
ABI2 is a platform that uses nanotubes to enhance the performance of existing diagnostic tests. The technology is based on a simple and cost-effective method of creating nanotubes from a polymer solution. The resulting nanotubes are incredibly stable and have a high surface area, which allows them to interact strongly with biological samples.
The ABI2 platform works by immobilizing a protein target inside the nanotube. This allows the target to bind to the nanotube and trigger a reaction that can be detected by the diagnostic test. The reaction is highly sensitive and can detect the presence of the protein target at a low concentration.
The Benefits of ABI2
BI2 has the potential to replace existing diagnostic methods because it is faster, cheaper, and more sensitive than existing methods. The technology has the potential to revolutionize the field of diagnostics, making it possible to diagnose diseases at an early stage and save lives.
One of the key benefits of ABI2 is its high sensitivity. The technology is able to detect the presence of protein targets at concentrations that are much lower than what is required by existing diagnostic methods. This means that researchers can detect diseases at an early stage and can also detect smaller amounts of disease, which is important for patients with reduced test sensitivity.
Another benefit of ABI2 is its cost-effectiveness. The technology is based on a simple and cost-effective method of creating nanotubes, which makes it an affordable platform for researchers to use. This means that researchers can use ABI2 to test for a wide range of diseases, without breaking the bank.
The Potential for Drug Targets
The ABI2 technology has the potential to be a drug target. By using nanotubes to immobilize protein targets, researchers can create a novel drug delivery system that can target specific proteins and trigger specific reactions. This has the potential to revolutionize the field of drug development and treatments.
In addition to its potential as a drug target, ABI2 has the potential as a biomarker. By using the technology to test for specific proteins, researchers can monitor the effectiveness of a drug or the effectiveness of a particular treatment. This has the potential to revolutionize the field of diagnostics and allow for more personalized medicine.
The ABI2 technology has the potential to revolutionize the field of diagnostics and drug development. By using nanotubes to enhance the sensitivity and accuracy of existing diagnostic tests, ABI2 has the potential to replace existing methods and save lives. Additionally, the technology has the potential to be a drug target and biomarker, which can trigger new research and development in the field of medicine.
Protein Name: Abl Interactor 2
Functions: Regulator of actin cytoskeleton dynamics underlying cell motility and adhesion. Functions as a component of the WAVE complex, which activates actin nucleating machinery Arp2/3 to drive lamellipodia formation (PubMed:21107423). Acts as regulator and substrate of nonreceptor tyrosine kinases ABL1 and ABL2 involved in processes linked to cell growth and differentiation. Positively regulates ABL1-mediated phosphorylation of ENAH, which is required for proper polymerization of nucleated actin filaments at the leading edge (PubMed:7590236, PubMed:8649853, PubMed:10498863). Contributes to the regulation of actin assembly at the tips of neuron projections. In particular, controls dendritic spine morphogenesis and may promote dendritic spine specification toward large mushroom-type spines known as repositories of memory in the brain (By similarity). In hippocampal neurons, may mediate actin-dependent BDNF-NTRK2 early endocytic trafficking that triggers dendrite outgrowth (By similarity). Participates in ocular lens morphogenesis, likely by regulating lamellipodia-driven adherens junction formation at the epithelial cell-secondary lens fiber interface (By similarity). Also required for nascent adherens junction assembly in epithelial cells (PubMed:15572692)
More Common Targets
ABI3 | ABI3BP | ABITRAM | ABL1 | ABL2 | ABLIM1 | ABLIM2 | ABLIM3 | ABO | ABR | ABRA | ABRACL | ABRAXAS1 | ABRAXAS2 | ABT1 | ABTB1 | ABTB2 | ABTB3 | ACAA1 | ACAA2 | ACACA | ACACB | ACAD10 | ACAD11 | ACAD8 | ACAD9 | ACADL | ACADM | ACADS | ACADSB | ACADVL | ACAN | ACAP1 | ACAP2 | ACAP3 | ACAT1 | ACAT2 | ACBD3 | ACBD4 | ACBD5 | ACBD6 | ACBD7 | ACCS | ACCSL | ACD | ACE | ACE2 | ACE2-DT | ACE3P | ACER1 | ACER2 | ACER3 | Acetyl-CoA Carboxylases (ACC) | Acetylcholine Receptors (Nicotinic) (nAChR) | ACHE | Acid-Sensing Ion Channel (ASIC) | ACIN1 | ACKR1 | ACKR2 | ACKR3 | ACKR4 | ACKR4P1 | ACLY | ACMSD | ACO1 | ACO2 | ACOD1 | ACOT1 | ACOT11 | ACOT12 | ACOT13 | ACOT2 | ACOT4 | ACOT6 | ACOT7 | ACOT8 | ACOT9 | ACOX1 | ACOX2 | ACOX3 | ACOXL | ACOXL-AS1 | ACP1 | ACP2 | ACP3 | ACP4 | ACP5 | ACP6 | ACP7 | ACR | ACRBP | ACRV1 | ACSBG1 | ACSBG2 | ACSF2 | ACSF3 | ACSL1 | ACSL3 | ACSL4 | ACSL5